Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorPeking University People's Hospital
About this trial
Lung malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. CDH3 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous epithelial cells. A new PET probe, 68Ga-TOI-1, targeting CDH3 has been developed with better affinity and selectivity than previous probes. Preclinical data support its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of lung tumors, providing a new and precise evaluation method for lung malignant tumors.
Eligibility criteria
Qualifiers
Age ≥ 18 years, male or female, with an ECOG performance status of 0 or 1;
Availability of complete clinical and imaging data;
Life expectancy ≥ 12 weeks;
Hematology, liver and kidney function meeting the following criteria: Hematology: WBC ≥ 4.0 × 10⁹/L or neutrophils ≥ 1.5 × 10⁹/L, PLT ≥ 100 × 10⁹/L, Hb ≥ 90 g/L; PT or APTT ≤ 1.5 × ULN; Liver and kidney function: T-Bil ≤ 1.5 × ULN, ALT/AST ≤ 2.5 × ULN, ALP ≤ 2.5 × ULN; BUN ≤ 1.5 × ULN, SCr ≤ 1.5 × ULN;
Disqualifiers
Women who are planning pregnancy, pregnant, or breastfeeding;
History of other malignant tumors or prior receipt of other anti-tumor therapies;
Poor or missing PET scan image quality of the probe that fails to meet analysis standards;
Presence of claustrophobia or other mental illnesses;
Trial design
Treatments tested in this trial
- PET/CT scans
Treatment groups
80 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov